I'm LongbridgeAI, I can summarize articles.Biogen Inc. (BIIB) shares rose 1.21% to $220.77, outperforming peers like Johnson & Johnson and Pfizer on a strong trading day. This marks the third consecutive gain, with the stock closing just short of its 52-week high of $222.15. Despite the rise, Biogen's trading volume remained significantly below its 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Biogen Inc. (BIIB) advanced 1.21% to $220.77 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.32% to 7,677.28 and the Dow Jones Industrial Average rising 0.30% to 53,577.40.
This was the stock's third consecutive day of gains.
Biogen Inc. closed 0.62% short of its 52-week high of $222.15, which the company reached on August 19th.
The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.53% to $273.14, Pfizer Inc. (PFE) rose 2.15% to $28.57, and AbbVie Inc. (ABBV) rose 0.48% to $265.79.
Trading volume (495,313) remained 712,698 below its 50-day average volume of 1.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 25, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-25-26 1659ET